Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer. Strong support from leading investors and global pharma partners continues to ...

Journal Editorial Report: The Fed Chief signals rate cuts are coming. As we saw during the Covid pandemic, lab-created experiments can wreak havoc when they escape their confines. Once released, they ...

Impaired β-cell function and insufficient β-cell mass compensation are twin pathogenic features that underlie type 2 diabetes (T2D). Current therapeutic strategies continue to evolve to improve ...

New York, Sept. 11, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has ...

The FDA approved imlunestrant for treatment of certain adults with breast cancer who experience disease progression after at least one prior line of endocrine therapy.